Cogent Biosciences director Arlene Morris sells $1.69m shares

Cogent Biosciences director Arlene Morris offloaded shares worth approximately $1.69 million on August 27, 2026. The sale was conducted under a pre-established Rule 10b5-1 trading plan, which Morris had put in place on May 28, 2026. The shares were traded at a weighted average price ranging from $37.0925 to $37.5396 per share. Since the sale, the stock price has declined to $34.99, though it has still increased by 189% over the past year.

Prior to the shares sale, Morris purchased 45,510 shares through the exercise of fully vested stock options on the same day, incurring a total cost of around $245,497. Despite analysts maintaining a bullish outlook on Cogent Biosciences, with price targets ranging from $45 to $62, the company currently holds liquid assets that surpass its short-term obligations, even though it is operating at a loss.